Zacks Research Lowers Earnings Estimates for AstraZeneca

AstraZeneca PLC (NASDAQ:AZN - Free Report) - Research analysts at Zacks Research reduced their Q2 2025 earnings per share (EPS) estimates for shares of AstraZeneca in a report released on Tuesday, May 20th. Zacks Research analyst R. Department now expects that the company will post earnings of $1.08 per share for the quarter, down from their previous estimate of $1.10. The consensus estimate for AstraZeneca's current full-year earnings is $4.51 per share. Zacks Research also issued estimates for AstraZeneca's Q3 2025 earnings at $1.12 EPS, Q4 2025 earnings at $1.06 EPS, FY2025 earnings at $4.50 EPS, Q4 2026 earnings at $1.32 EPS and FY2027 earnings at $5.57 EPS.

A number of other research analysts also recently commented on the stock. UBS Group raised shares of AstraZeneca from a "neutral" rating to a "buy" rating in a research note on Thursday, February 13th. BNP Paribas initiated coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price target for the company. Finally, Morgan Stanley assumed coverage on shares of AstraZeneca in a report on Wednesday, February 12th. They issued an "overweight" rating on the stock. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $88.00.

AstraZeneca Stock Performance

AstraZeneca stock opened at $69.68 on Thursday. The stock has a fifty day moving average price of $70.06 and a 200 day moving average price of $69.43. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. AstraZeneca has a 52 week low of $61.24 and a 52 week high of $87.68. The firm has a market capitalization of $216.09 billion, a P/E ratio of 30.83, a PEG ratio of 1.42 and a beta of 0.40.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. The business had revenue of $13.59 billion for the quarter, compared to analysts' expectations of $13.71 billion. AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. The business's revenue for the quarter was up 7.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.06 EPS.

Institutional Trading of AstraZeneca

Several large investors have recently added to or reduced their stakes in AZN. Banque Transatlantique SA acquired a new stake in shares of AstraZeneca in the fourth quarter valued at about $26,000. Confluence Investment Management LLC purchased a new position in AstraZeneca in the 1st quarter worth approximately $27,000. Larson Financial Group LLC grew its position in AstraZeneca by 297.9% in the first quarter. Larson Financial Group LLC now owns 386 shares of the company's stock valued at $28,000 after acquiring an additional 289 shares in the last quarter. Mascagni Wealth Management Inc. purchased a new stake in shares of AstraZeneca during the fourth quarter valued at approximately $29,000. Finally, FNY Investment Advisers LLC acquired a new position in shares of AstraZeneca during the first quarter worth $29,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.